



2 September 2022

## **Wholly owned US subsidiary, Sierra Sage Herbs LLC. launches new product range – secures US\$214,000 purchase order for 400+ select Walmart stores**

### **Highlights**

- **New plant-based product range targeting anti-aging, acne and eczema developed and to be sold through Sierra Sage Herb's ("SSH") existing Green Goo brand**
- **Launch complemented by US\$214,000 purchase order from US distributor, which has placed the products in 400+ select Walmart stores across the US**
- **Walmart is a major American multinational retail corporation that operate a chain of hypermarkets, department stores and grocery stores across the US**
- **Delivery anticipated to occur during September, with product to be made available to consumers during Q3 2022**
- **Walmart is an existing stockist of SSH's existing products, alongside other major US retailers including Walgreens, Safeway and CVS Pharmacy, amongst others**
- **Additional distribution expansion and sales initiatives underway**

**Creso Pharma Limited (ASX: CPH, FRA: 1X8) ('Creso Pharma' or 'the Company')** is pleased to announce that its wholly-owned US CBD and plant-based products division, Sierra Sage Herbs LLC. ("Sierra Sage Herbs" or "SSH") will launch its new all natural skincare collection in approximately 400 select Walmart stores across the US. The launch includes a preliminary purchase order from a distributor valued at US\$214,000 for delivery and stocking in during Q3 2022.

The Company will launch its new 'Plants for your Face & Body' skincare collection under SSH's established Green Goo brand. The range utilises the brand's proprietary lipid infusion process and infuses healing herbs and plant based botanicals.

The collection includes a range of targeted plant-based solutions focused on anti-aging, acne and eczema. SSH will deliver a variety of face and body washes, serums, roll-ons and sticks providing consumers with a number of delivery methods.

Walmart is a major American multinational retail corporation that operate a chain of hypermarkets, department stores and grocery stores across the US. Walmart are an existing stockist of SSH's Green Goo product, alongside other major retailers including CVS Pharmacy, Walgreens, and Safeway amongst others.

Creso Pharma is confident that the new range will resonate well with consumers. The preliminary purchase order also highlights the ongoing demand SSH is witnessing for its Green Goo range.

The Company expects the range to be on shelves shortly after the expected September 2022 delivery. SSH management are also exploring a number of other potential distribution agreements through existing points of sale to drive revenue growth.



**Management commentary:**

**CEO and Managing Director Mr William Lay said:** *“Sierra Sage Herb’s new collection was developed following considerable R&D with respect to natural body care. We are confident that the range will serve consumers looking to make a lifestyle change and utilise a healthier option for their skin.*

*“To stock our product range at Walmart, one of the US’ most widely recognised retailers, is a major achievement for SSH and highlights the potential demand for the Company’s products.*

*“We anticipate delivery for the maiden order will occur during September, with products to be on shelves in the weeks following. SSH are working with other retail groups and potential stockist to expand distribution and drive sales growth. Additional updates in this regard will be made as developments materialise.”*

**Corporate Update:**

Further to its announcements dated 21 January 2020 and 26 March 2021, the Company would also like to advise that it has entered a Deed of Novation and Amendment to its Corporate Advisory and Transaction Mandates with Everblu Capital Pty Ltd and Everblu Capital Corporate Pty Ltd (“Deed”). Adam Blumenthal is a director of Creso Pharma Limited and is also a director of both Everblu Capital Pty Ltd and Everblu Capital Corporate Pty Ltd. This Deed novates the Corporate Advisory and Transaction Mandates from “Everblu Capital Pty Ltd” to “Everblu Capital Corporate Pty Ltd”(“Everblu”). This Deed also increases the notice period for the termination of the Corporate Advisory and Transaction Mandates by the Company from 6 months to 12 months.

**-Ends-**

**Authority and Contact Details**

This announcement has been authorised for release by the Board of Creso Pharma Limited.

For further information, please contact:

**Investor Enquiries**

Creso Pharma Limited  
E: [info@cresopharma.com](mailto:info@cresopharma.com)  
P: +61 (0) 497 571 532

**About Creso Pharma**

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health.

Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: [www.cresopharma.com](http://www.cresopharma.com)

**Creso Pharma offices:****Australia**

Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

**Switzerland**

Allmendstrasse 11, 6312 Steinhausen, Schweiz

**Canada**

59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

**Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.